The deal provides additional intellectual property to protect Zertane ODT formulation, that allows for rapid oral absorption, without the need for liquids.
The acquisition of the drug delivery technology will enhance and allow Ampio’s filing of marketing authorisation applications for product regulatory approvals of Zertane globally.
Ampio Pharmaceuticals CEO Don Wingerter said the acquisition of the drug delivery technology will help in the manufacturing and commercialisation plan for Zertane.
”We are committed to complete the development of a combination product of Zertane with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction,” Wingerter added.
The close of the transaction is subject to customary conditions, including a certain third party consent and completion of a technology and materials transfer plan.